Atara Biotherapeutics (ATRA) Stock: Buy, Sell, or Hold?
ATRA - Atara Biotherapeutics, Inc
$8.59
-0.84 (-8.91%)
▼
5d:
-6.43%
30d:
+0.59%
90d:
+11.41%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 11, 2026
17d
Get Alerted When ATRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ATRA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ATRA shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$28.14
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$17.47
50.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ATRA is currently trading at $8.59, which is considered oversold relative to its 30-day fair value range of $8.69 to $9.65. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.6) compared to its historical average (13.0). Remarkably, the market is currently pricing in an annual earnings decline of 24.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ATRA is in a downtrend. The price is currently testing key support at $8.55. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.9% recently.
Market Sentiment: ATRA scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.67 (+59.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATRA is in a downtrend. The price is currently testing key support at $8.55. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.9% recently.
Market Sentiment: ATRA scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.67 (+59.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$8.69 -
$9.65
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.9%)
- BULLISH: Trading 59.1% below Wall St target ($13.67)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.69 -
$9.65
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$8.55
Resistance Level
$9.99
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.56
Wall Street Target
$13.67
(+59.1%)
Revenue Growth (YoY)
-96.4%
Profit Margin
-269.4%
Valuation Discount vs History
-24.6% cheaper
PE vs Historical
5.6 vs 13.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-24.6%
(market-implied from PE analysis)
1-Year Target
$7.73
(-10%)
2-Year Target
$6.96
(-19%)
3-Year Target
$6.26
(-27%)
3-Yr Target (if PE normalizes)
(PE: 6→13)
$14.64
(+71%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.6 to 13.0
Stabilization Target:
$20.08
(+133.8%)
PE Expansion Potential:
+133.8%
Share & Embed Analysis
Last updated: October 23, 2026 8:54 PM ET
Data refreshes hourly during market hours. Next update: 9:54 PM
Data refreshes hourly during market hours. Next update: 9:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 73 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 72 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 69 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 43 HOLD |
